UK survival rates for five common cancers drastically lag behind other high-income nations, shocking data shows.
Just 7.9 per cent of Brits diagnosed with pancreatic cancer in 2014 could expect to still be alive five years later.
In Australia, the odds were almost double at 14.9 per cent.
It comes as top experts today warned that Britain is woefully 15 years behind other countries because of a lack of chemotherapy and radiotherapy.
The damning report found thousands of patients are being denied potentially life-saving treatment on the NHS.
Even for patients who did get treatment, they were forced to endure longer waits — raising the risk of their disease spreading and slashing survival odds.
Two new studies part-funded by Cancer Research UK and published in the Lancet Oncology show people in the UK are treated with chemotherapy and radiotherapy less often than in Norway, Canada and Australia. Graph shows average chemo use for all types of cancer
The research was carried out by the International Cancer Benchmarking Partnership and is the first to examine treatment differences for eight cancer types across three continents. Graph shows the average radiotherapy use
Leading experts slammed the ‘missed opportunity’ for cancer patients and demanded urgent action to tackle the crisis.
Survival rates depend entirely on the type of cancer, with some known to be more aggressive than others.
The particular subset of cancer can also have an effect.
The figures, which assess the rate between 2010 and 2014, show the UK was the worst of each country examined for cancer of the pancreas, stomach, lung, bowel and ovaries.
Bowel had the highest chance of survival after five years at 58.9 per cent.
Cancer-stricken woman, 68, has months to live after NHS doctors missed a 3cm tumour clearly visible on scan
A woman has just months to live after doctors missed a golf ball-sized tumour clearly visible on a scan – then dismissed her concerns for two years as the cancer spread.
In the two decades beforehand, Anne Shaw, 68, had been treated successfully for breast and ovarian cancer, which put her at higher risk of having cancer again.
But doctors at St James’s University Hospital in Leeds failed to spot a 3.3cm tumour on her ovary during a routine scan in summer 2019.
And they then failed to take her seriously when she returned to the hospital in February 2020 complaining of symptoms of ovarian cancer and raising concerns it may have returned.
‘The registrar I saw had clearly not read my medical records,’ Anne said. ‘He felt my stomach area briefly and told me I was fine, despite what I was telling him about my history.’
It was only after she went back to her GP in September 2021 that she was fast-tracked to a cancer specialist and the cancer was finally diagnosed that autumn. By that time, it had spread over large parts of her bowel.
Patients in Australia, Canada and Norway, however, had significantly better odds, logging an average rate of seven in 10 (70.8 per cent), two thirds (66.8 per cent) and 65.4 per cent respectively.
Ovarian did not fare any better, with just 37.1 per cent of Brits diagnosed with the cancer between 2010 and 2014 expected to still be alive five years later.
By contrast, the rate stood at 46.2 per cent, 43.2 per cent and 40.3 per cent in Norway, Australia and Canada.
The UK five-year-survival rate for stomach cancer was also 20.8 per cent in 2010-14.
Australia logged 32.8 per cent, while Canada and Norway reported figures of 29.8 per cent and 26.9 per cent.
It comes as fresh data released today showed the UK was ‘still around 10 to 15 years behind’ nations like Australia, Canada and Norway, who are far more likely to give patients chemo and radiotherapy.
Renowned experts warned the findings help explain why UK cancer survival rates are drastically lower than in other developed countries.
Dr John Butler, clinical lead for the International Cancer Benchmarking Partnership and an ovarian cancer surgeon, said: ‘For many aggressive cancers — such as ovarian, lung and pancreatic cancer, it’s vital that people are diagnosed and start treatment as soon as possible.
‘Lower use of chemotherapy and radiotherapy in the UK could impact people’s chances of survival, especially for older patients.
‘Although we have made progress, the last benchmark showed that cancer survival in the UK is still around 10 to 15 years behind leading countries.
‘This study captures missed opportunities for patients in the UK to receive life-prolonging treatment.’
The researchers from University College London examined data from 780,000 people to compare how treatment for eight cancer types differed in Australia, Canada, Norway and the UK between 2012 and 2017.
Just under a third (31.5 per cent) of UK patients received chemotherapy, compared with 38.5 per cent in Canada, 39.1 per cent in Norway and 42.1 per cent in Australia.
Meanwhile, 19.8 per cent of UK patients received radiotherapy, compared with 25.7 per cent in Canada, 22.5 per cent in Norway and 23.9 per cent in Australia.
The treatment lottery was particularly stark among older patients, which critics have described as ‘blatant ageism’.
Just 2.4 per cent of UK patients aged 85 and over received chemotherapy, compared to 8.1 per cent in Australia and 14 per cent in parts of Canada.
The studies, funded by Cancer Research UK and the International Cancer Benchmarking Partnership, were published in the Lancet Oncology.
Samantha Harrison, of Cancer Research UK, said: ‘What we can now say is that treatment is clearly playing a role in survival differences.
‘The countries that have better outcomes tend to have both more and quicker use of treatments.
‘Use of chemotherapy and radiotherapy is less in this country, particularly in older patients, and this is affecting survival.’
Caroline Abrahams, director of Age UK, added the research demonstrated older people were prone to ‘unequal treatment’ within the NHS.
She said: ‘While it is true that older people are more likely to live with multiple conditions, that alone is not a valid reason to exclude them.
‘With the right support and clinical expertise, many older people can and would, still choose to benefit from cancer treatment.’
Dennis Reed, of over-60s campaign group Silver Voices, said: ‘The NHS shows time and time again that it is systemically ageist.
‘The older you get, the less likely you are to be diagnosed in good time, and even then your chances of medical or surgical intervention are much less.
Alongside stark variations in treatment, British patients had some of the longest waits to start cancer care, typically waiting 81 days in Labour-run Wales.
Health leaders have consistently warned that an array of key cancer targets have not been hit in recent years.
They have also estimated 40,000 cancers went undiagnosed during the first year of pandemic alone.
Official NHS data for December on cancer waiting times shows just seven in 10 (74.2 per cent) of patients urgently referred for suspected cancer were diagnosed or had cancer ruled out within 28 days. The target is 75 per cent.
Anne Shaw (pictured with her husband Louis) has won a six-figure payout after NHS medics failed to detect her cancer and dismissed her concerns for two years
While the level of progress for cancer survival for some forms of the disease has been rapid, such as for breast and prostate cancers, others, like those for lung and pancreas have only improved at a snail’s pace
Just nine in ten (91.1 per cent) waiting a month or less for their first cancer treatment to begin after a decision to proceed with surgery, chemotherapy or radiotherapy.
The target is 96 per cent but this has never been met.
An NHS spokesman said: ‘More people than ever are being diagnosed at an early stage of cancer and more treatment options are available.’
A Department of Health and Social Care spokesperson said: ‘These figures cover only the period from 2012-2017.
‘Since then, we have made significant investment in cancer diagnosis and treatment, including £162 million towards radiotherapy equipment and £2.3 billion to launch 160 Community Diagnostic Centres across England, which will help us achieve our aim of catching 75 per cent of all cancers at stage 1 or 2 by 2028.’
They added: ‘Cutting waiting lists is one of the government’s top five priorities, and we have treated record numbers of patients over the last year.
‘Survival rates are also improving across almost all types of cancer, and we will shortly legislate to create the first smokefree generation — the biggest single public health intervention in decades.’
